JCO precision oncology 2025 Oct 30
Multi-Institution Analysis of Tarlatamab for the Treatment of -Mutant Transformed Small Cell Lung Cancer.
Related Questions
Furthermore, should adding immunotherapy be considered?
New answer by Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR (November 2, 2025)
Also, tarlatamab doesn’t work well in these despite high DLL3 expression, per this small series Cooper et al., PMID 41166675.